Get started
Author

Takafumi Tsushima

Observed names: T. Tsushima, Tsushima, Takafumi
ORCID: 0000-0002-4776-4249
Observed ORCID: 0000-0002-4776-4249
OpenAlex ID: A5017179643
Pre‐treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron‐emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice
2020 · Toshiki Terao, Youichi Machida, et al. · British Journal of Haematology · 36
PDF
Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
2021 · Akihiro Kitadate, Toshiki Terao, et al. · Cancer Science · 30
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure
2021 · Ayumi Kuzume, Rikako Tabata, et al. · British Journal of Haematology · 28
Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma
2021 · Toshiki Terao, Youichi Machida, et al. · European Radiology · 20
Antibody response to COVID-19 vaccination in patients with lymphoma
2022 · Kentaro Narita, So Nakaji, et al. · International Journal of Hematology · 19
PDF
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
2022 · Takafumi Tsushima, Toshiki Terao, et al. · International Journal of Hematology · 18
PDF
Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review
2022 · Toshiki Terao, Takafumi Tsushima, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16
Prognostic Impact of Metabolic Heterogeneity in Patients With Newly Diagnosed Multiple Myeloma Using 18F-FDG PET/CT
2021 · Toshiki Terao, Youichi Machida, et al. · Clinical Nuclear Medicine · 16
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
2022 · Toshiki Terao, Takeshi Yamashita, et al. · International Journal of Hematology · 14
PDF
Depletion of CD38 ‐positive regulatory T cells by anti‐CD38 monoclonal antibodies induces a durable response to SARS‐CoV ‐2 vaccination in patients with plasma cell dyscrasia
2022 · Toshiki Terao, Takashi Naduka, et al. · British Journal of Haematology · 14
Evaluation of the safety and efficacy of daratumumab outside of clinical trials
2019 · Hiroki Kobayashi, Takafumi Tsushima, et al. · International Journal of Hematology · 14
Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
2021 · Toshiki Terao, Ken-ichi Matsuoka, et al. · Frontiers in Oncology · 13
PDF
Baseline total lesion glycolysis combined with interim positron emission tomography‐computed tomography is a robust predictor of outcome in patients with peripheral T‐cell lymphoma
2020 · Akihiro Kitadate, Kentaro Narita, et al. · Cancer Medicine · 13
PDF
Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation
2023 · Takafumi Tsushima, Shin-Ichi Masuda, et al. · Annals of Hematology · 12
PDF
Light chain deposition disease involving kidney and liver in a patient with IgD myeloma
2021 · Takafumi Tsushima, Tomo Suzuki, et al. · BMC Nephrology · 10
PDF
Antibody status following booster vaccination against SARS‐CoV ‐2 virus in patients with haematologic malignancies
2022 · Daisuke Ikeda, Toshiki Terao, et al. · British Journal of Haematology · 9
Management of lymphoma-associated chylothorax by interventional radiology and chemotherapy: a report of five cases
2022 · Ami Fukumoto, Toshiki Terao, et al. · International Journal of Hematology · 8
Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma
2020 · Hiroki Kobayashi, Toshiki Terao, et al. · Cancer Medicine · 7
PDF
Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL
2022 · Toshiki Terao, Takafumi Tsushima, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib
2022 · Daisuke Ikeda, Toshiki Terao, et al. · Frontiers in Medicine · 6
PDF
Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma
2021 · Toshiki Terao, Youichi Machida, et al. · Scientific Reports · 6
PDF
Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old approach
2020 · Toshiki Terao, Takafumi Tsushima, et al. · eJHaem · 6
Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma
2025 · Yoshikazu Utsu, Yuki Isono, et al. · Annals of Hematology · 5
PDF
Clinical Characteristics and Outcomes of Cyclin D1–Positive AL Amyloidosis
2023 · Takafumi Tsushima, Toshiki Terao, et al. · American Journal of Clinical Pathology · 5
PDF
Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
2021 · Kentaro Narita, Daisuke Miura, et al. · Scientific Reports · 4
PDF
Works count: 54
Citation count: 362
H-index: 13
I10-index: 15
Year
Topic
Type